CARBIOS
26.1.2023 06:46:34 CET | Business Wire | Press release
Regulatory News:
This press release features multimedia. View the full release here: https://www.businesswire.com/news/home/20230125005432/en/
(L-R): Martine BRISSET (General Manager Biodegradation Division, Senior Vice President of Carbios Group, and Executive Committee Member) and Delphine DENOIZE (Innovation Programs Funding, Regulation and LCA Director, and Executive Committee Member)
Carbios (Euronext Growth Paris: ALCRB), a pioneer in the development and industrialization of biological technologies for reinventing the life cycle of plastics and textiles, has strengthened its leadership team with the appointment of Martine BRISSET as Senior Vice President from 1 January 2023. Martine will manage the Biodegradation Division and supervise the Human Resources, Legal, Regulatory, Project Management, Quality Health and Safety departments. Martine BRISSET joins the Group's Executive Committee, as does Delphine DENOIZÉ, who remains Innovation Programs Funding, Regulation and LCA Director with an expanding team.
"Over the past six months, our teams have grown significantly in order to achieve our ambitious targets, and I am very pleased to appoint Martine and Delphine to the Executive Committee," commented Emmanuel LADENT, Chief Executive Officer of Carbios. "Their proven track records, notably within the Carbios Group, strengthen the top management’s expertise and reinforces the diversity of skills needed to succeed in this pivotal year for Carbios’ industrialization and commercialization.”
Martine BRISSET, Senior Vice President of Carbios : “After having supervised the production of thousands of tons of plastic destined for the packaging sector, I am now focused on reducing plastic pollution with our biodegradation and biorecycling solutions. I'm very excited to take on this awesome and exciting challenge, one that makes sense for future generations and for industry."
Martine BRISSET has over 30 years of General Management experience in major international groups within the plastic and paper packaging industry, most notably at Amcor, Huhtamaki, Linpac and Klockner Pentaplast. Since 2021, she has held the position of General Manager of Carbiolice in order to integrate this high-potential subsidiary dedicated to biodegradation within the Carbios Group. In her new position as Senior Vice President of Carbios, her main mission will be to successfully deploy the biodegradation technology, facilitate the international expansion of Carbios' activities, organise the recruitment and training of the Group's employees. With numerous recruitments planned throughout the company in 2023, building Carbios’ attractivity will be a strategic topic.
Delphine DENOIZÉ, Innovation Programs Funding, Regulation and LCA Director : "What drives me is the satisfaction of seeing a project through, from concept to reality. At Carbios, all our projects have a positive impact on the environment, and it’s rising to this challenge that makes me passionate about my work. By becoming a member of the Executive Committee, I will support these projects even more enthusiastically, in terms of their structuring and funding, but also in terms of their regulatory compliance and environmental performance.”
After several years working in innovation within the agricultural industry, it was during her time at Céréales Vallées cluster that Delphine DENOIZÉ discovered and assisted in the creation of Carbios. She joined the company in 2016 and was one of its first twenty employees. Initially in charge of Innovation Funding and Regulation, then Project Management for PET biorecycling, she now oversees all the Group’s projects. Her responsibilities include French and European public funding for innovation, regulatory compliance of processes and products around the world, and assessment of their environmental impact through specific tools such as Life Cycle Assessment.
Executive Committee Members of Carbios Group:
- Emmanuel LADENT, Chief Executive Officer
- Lionel ARRAS, Industrial Development Director
- Mathieu BERTHOUD, Sourcing and Public Affairs Director
- Pascal BRICOUT, Chief Strategy and Financial Officer
- Martine BRISSET, General Manager Biodegradation Division and Senior Vice President of Carbios Group
- Delphine DENOIZÉ, Innovation Programs Funding, Regulation and LCA Director
- Stéphane FERREIRA, Chief Business Officer
- Lise LUCCHESI, Intellectual Property Director
- Prof. Alain MARTY, Chief Scientific Officer
Visit Carbios’ website for biographies of each individual member: https://www.carbios.com/en/governance/
About Carbios
Established in 2011 by Truffle Capital, Carbios is a green biotech company, developing biological and innovative processes. Through its unique approach of combining enzymes and plastics, Carbios aims to address new consumer expectations and the challenges of a broad ecological transition by taking up a major challenge of our time: plastic and textile pollution. Carbios deconstructs any type of PET (the dominant polymer in bottles, trays, textiles made of polyester) into its basic components which can then be reused to produce new PET plastics with equivalent quality to virgin ones. This PET innovation, the first of its kind in the world, was recently recognized in a scientific paper published in front cover of the prestigious journal Nature. Carbios successfully started up its demonstration plant in Clermont-Ferrand in 2021. It has now taken another key step towards the industrialization of its process with the construction of a first-of-a-kind unit in partnership with Indorama Ventures.
In 2017, Carbios and L’Oréal co-founded a consortium to contribute to the industrialization of its proprietary recycling technology. Committed to developing innovative solutions for sustainable development, Nestlé Waters, PepsiCo and Suntory Beverage & Food Europe joined this consortium in April 2019. In 2022, Carbios signed an agreement with On, Patagonia, PUMA, and Salomon, to develop solutions promoting the recyclability and circularity of their products.
The Company has also developed an enzymatic biodegradation technology for PLA-based (a bio sourced polymer) single-use plastics. This technology can create a new generation of plastics that are 100% compostable at ambient temperatures, even in domestic conditions, integrating enzymes at the heart of the plastic product.
For more information, please visit carbios.com / Twitter: Carbios / LinkedIn: Carbios / Instagram: insidecarbios
Carbios (ISIN FR0011648716/ALCRB) is eligible for the PEA-PME, a government program allowing French residents investing in SMEs to benefit from income tax rebates.
Translation is for information purposes only.
In case of discrepancy between the French and the English version of this press release, the French version shall prevail
To view this piece of content from cts.businesswire.com, please give your consent at the top of this page.
View source version on businesswire.com: https://www.businesswire.com/news/home/20230125005432/en/
About Business Wire
Subscribe to releases from Business Wire
Subscribe to all the latest releases from Business Wire by registering your e-mail address below. You can unsubscribe at any time.
Latest releases from Business Wire
vVARDIS Announces Investment from Apollo—Achieves Unicorn Status27.4.2026 14:51:00 CEST | Press release
Investment will support global commercial expansion of the Curodont™ technology platform, the first and only non-invasive peptide-containing formulations designed to treat tooth decay drill-free throughout the depth of the lesion vVARDIS Holding AG (“vVARDIS”), a high-growth dental medtech company pioneering non-invasive cavity treatment, today announced a strategic minority investment from Apollo-managed funds (“Apollo Funds”). The investment will support vVARDIS’ next phase of global growth and commercial expansion, including the continued rollout of its Curodont™ suite of products. The investment establishes vVARDIS as one of Europe’s few privately owned, billion-dollar-plus, healthcare companies. vVARDIS’ founders and co-CEOs, Drs. Haley and Goly Abivardi, will retain a substantial majority shareholding in the company. vVARDIS is redefining the treatment of cavities through its Curodont™ technology, the first and only commercially available non-invasive peptide-containing formulati
IAS Launches IAS Total TV Solutions Giving Marketers ‘Linear-like’ Transparency for Connected TV27.4.2026 14:30:00 CEST | Press release
‘IAS Total TV’ unlocks show, genre and rating transparency measurement across Disney, NBCUniversal, Paramount and Prime Video, plus multiple opted-in publishers using Publica enabling advertisers to enhance brand suitability while increasing campaign outcomes Integral Ad Science (IAS) today announced ‘IAS Total TV’, a new comprehensive suite of Connected TV (CTV) solutions designed specifically to bring ‘linear-like’ transparency to streaming TV. IAS Total TV can provide marketers with genre, rating, language, show and program-level data in aggregate from Disney, NBCUniversal, Paramount and Prime Video, in addition to multiple opted-in publishers using Publica. IAS Total TV integrates content insights, media quality, supply path and outcomes into a unified view within the IAS Signal user interface (UI). Advertisers can determine when and how they want their advertising to run alongside CTV content, ensuring brand-related and brand suitable environments. “As advertisers continue to doub
Riskified Study Finds Consumers Aren’t Ready to Hand Over Control as AI Transforms Shopping, with Over Half Afraid of Online Fraud27.4.2026 14:00:00 CEST | Press release
New Q1 2026 “Agentic Commerce Pulse” survey from Riskified reveals a growing trust gap in agent-driven commerce, as consumers embrace AI across the shopping journey but remain hesitant to hand over control amid concerns over fraud, security, and accountability Riskified (NYSE: RSKD), a global leader in ecommerce fraud and risk intelligence, today released the Q1 2026 edition of its Agentic Commerce Pulse, a quarterly research series tracking agentic commerce risks and consumer engagement. Following Riskified’s inaugural Q4 2025 survey, which first highlighted the rapid emergence of agent-driven commerce, the latest findings reveal a more complex reality: while AI adoption remains strong, consumer trust is not keeping pace. A widening gap is emerging between how shoppers use AI and how much control they are willing to give it. The survey, conducted among consumers across the United States and the United Kingdom, shows that AI is now firmly embedded in product discovery and decision-maki
Nine in 10 Expect Cross-Border M&A Surge, But 71% of Dealmakers Have Already Changed Course on Deals27.4.2026 14:00:00 CEST | Press release
90% of dealmakers expect cross-border M&A activity to increase over the next 12–24 months75% cite foreign direct investment screening as the biggest threat to deal completion88% report longer signing-to-close timelines than three years ago Cross-border M&A is set for a strong resurgence, with nine in 10 senior dealmakers expecting activity to increase over the next 12 to 24 months, according to new research from CSC, the leading provider of business administration and compliance solutions. However, despite this renewed momentum, execution risk is rising, with regulatory scrutiny and operational challenges making it harder to get deals over the line. CSC¹ surveyed 200 director level and above global dealmakers across private equity, corporate, legal, and advisory roles who have worked on cross-border transactions in the past two years. The report, The New Reality of Cross-Border M&A: More Deals, More Friction, explores how firms are navigating an increasingly complex global deal environ
Mundipharma announces positive topline results from Phase III ReSPECT trial assessing ▼REZZAYO® (rezafungin) for the prophylaxis of invasive fungal diseases in allogeneic haematopoietic stem cell transplantation patients27.4.2026 13:43:00 CEST | Press release
For Trade and Medical Media Only The study primary endpoint was met, showing non-inferiority vs. standard antimicrobial regimen in fungal-free survival at Day 90 Study showed favourable benefit for toxicity-related discontinuations and drug-drug interactions (DDIs) Rezafungin was well tolerated, with a safety profile comparable to standard antimicrobial regimens (SARs) Mundipharma today announced positive Phase III topline results from the global ReSPECT clinical trial evaluating REZZAYO® (rezafungin acetate) for prophylaxis of invasive fungal diseases (IFDs) in adult patients undergoing allogeneic haematopoietic stem cell transplantation (HSCT). The ReSPECT Phase III trial, one of the largest antifungal, multicentre, randomised, double-blind studies evaluated the efficacy and safety of once weekly rezafungin compared with a SAR for the prophylaxis of IFDs, including infections caused by Candida, Aspergillus, and Pneumocystis, in adults undergoing allogeneic HSCT. Patients undergoing a
In our pressroom you can read all our latest releases, find our press contacts, images, documents and other relevant information about us.
Visit our pressroom
